From: Sustained onabotulinumtoxinA therapeutic benefits in patients with chronic migraine over 3 years of treatment
Reasons for discontinuation of Onabotulinumtoxin-A treatment
N (%)
Lost to follow-up
3 (33.3%)
Financial limitations
1 (11.1%)
Patients significantly improved/ No additional sessions were needed
5 (55.5%)